Naratriptan Renata Pharmaceuticals (Ireland) (Naratriptan)

Naratriptan works by selectively stimulating serotonin 5‑HT1B and 5‑HT1D receptors in the brain. This causes constriction of dilated cranial blood vessels and blocks the release of pain‑triggering neuropeptides, thereby reducing migraine pain and related symptoms.

The exact dose of Naratriptan is determined by the prescribing healthcare professional based on individual patient factors. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for Naratriptan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Naratriptan belongs to the triptan class, which is generally more effective for moderate to severe migraine attacks than simple analgesics. Compared with other triptans, it has a longer half‑life, allowing a single dose to provide sustained relief, but individual response may vary.

Naratriptan tablets should be stored at ambient temperature, below 25 °C, in their original container to protect from moisture. Keep the product out of reach of children and avoid exposure to direct sunlight.

Naratriptan is taken orally, usually as a single tablet at the onset of a migraine attack. It should be swallowed whole with water and not crushed or chewed. Patients should follow the dosing instructions provided by their prescriber.

Serious risks include chest pain or tightness, which may signal cardiac ischemia, and serotonin syndrome, a potentially life‑threatening condition that can cause agitation, high fever, and muscle rigidity. Any such symptoms require immediate medical attention.

Naratriptan is contraindicated in individuals with uncontrolled hypertension, recent myocardial infarction or stroke, severe coronary artery disease, and those taking MAO inhibitors or other triptans. Patients with these conditions should discuss alternative therapies with their healthcare provider.